The Norwegian University of Science and Technology in Trondheim (NTNU) will conduct an investigator-initiated clinical Phase II trial with the diabetes vaccine Diamyd® administered directly into the lymph node in a limited number of patients newly diagnosed with Latent Autoimmune Diabetes in Adults (LADA).

The Drug Maker

Diamyd Medical is a Swedish diabetes company active in the field of pharmaceutical development. They develop the Diamyd® diabetes vaccine, an Antigen Based Therapy (ABT) based on the exclusively in-licensed GAD molecule. In-licensed technologies for GABA and Gliadin also have potential to become “a key piece of the puzzle of a future solution to prevent, treat or cure autoimmune diabetes and other inflammation-related conditions.

A microcap valued emerging biotech, their firm is estimated to have about 25 employees. For clinical trials, they have partnered with universities, such as the Norwegian center (covered in this story) as well as Linköping University and Uppsala University both of Sweden.

Lead Investigator on the Investigational Product

Ingrid K. Hals, PhD, notes that “We have identified the diabetes vaccine Diamyd as one of the most promising therapies for LADA.” She continued, saying, “There is a great need within LADA for new treatments such as Diamyd that can be tailored for autoimmune diseases.

The Norwegian University of Science and Technology

The Norwegian University of Science and Technology has roots dating back to 1760. A public research university, its main campus sits in Trondheim and their satellite campuses can be found in Gjøvik and Ålesund; it is the largest university in Norway following the merger in 2016 when it surpassed the country’s oldest university—the University of Oslo. NTNU in its current form was established in 1996 by the merger of the former University of Trondheim and other university-level institutions. Its current endowment equals about $1.1 billion.

The public Norwegian university operates a robust clinical research operation and TrialSite News believes that Norway is “an underutilized” nation for clinical research. For example, Norway has a transparent system for treatment distribution as noted on the NTNU website. Moreover, a coordinated and unified public health services with a collaborative culture combines with a population motivated by health and progress in clinical research. Norway is a wealthy country and the region of NTNU has many highly qualified professionals, not to mention a sophisticated health informatics infrastructure.

Lead Research/Investigator

Ingrid K. Hals, PhD, NTNU

Call to Action: For those interested in an investigational approach to a diabetes vaccine, it will be of interest to monitor this investigator-initiated study in Norway—testing the Diamyd diabetes vaccine. TrialSite News will monitor the effort for our viewers.

Source: PR Newswire

Pin It on Pinterest